non-small cell lung cancer with EGFR mutation
Conditions
Interventions
carboplatin, pemetrexed, gefitinib
Sponsors
Kanagawa Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with histologically or cytologically confirmed NSCLC with EGFR mutation, clinical stage IIIB or IV, an expected survival of at least 12 weeks, age >20 years and < 75 years, Eastern Cooperative Oncology Group PS score 0-1, leukocyte count>=4,000/mm2, hemoglobin >=10 g/dl, platelet count >=100,000/mm2, total serum bilirubin <=1.5 mg/dl, aspartate aminotransferase and alanine aminotransferase <100 IU/L, serum creatinine <=1.5 mg/dl. Patients who had experienced postoperative recurrence were eligible, written informed consent was obtained from every patient.
Exclusion criteria
Exclusion criteria: Patients who had received chemotherapy or radiotherapy were excluded. Patients who have massive pleural effusion or pericardial effusion, who have uncontrolled cardiac disease, diabetes mellitus or hypertension, who have infectious disease, who have interstitial pneumonitis, were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, progression-free survival, anti-tumor effect, toxicity | — |
Countries
Japan
Contacts
Public ContactFumihiro Oshita
Kanagawa Prefectual Ashigarakami Hospital Comprehensive Medical Care
Outcome results
None listed